[go: up one dir, main page]

GT201600004A - Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen - Google Patents

Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen

Info

Publication number
GT201600004A
GT201600004A GT201600004A GT201600004A GT201600004A GT 201600004 A GT201600004 A GT 201600004A GT 201600004 A GT201600004 A GT 201600004A GT 201600004 A GT201600004 A GT 201600004A GT 201600004 A GT201600004 A GT 201600004A
Authority
GT
Guatemala
Prior art keywords
tiazolidina
morfolinilmetil
pirrol
diona
indol
Prior art date
Application number
GT201600004A
Other languages
English (en)
Inventor
Le Flohic Alexandre
Guidotti Jérôme
Letellier Philippe
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of GT201600004A publication Critical patent/GT201600004A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA NUEVA SAL DE LA 3-[(3-{[4-(4-MORFOLINILMETIL)-1H-PIRROL-2-IL]METILEN}-2-OXO-2,3-DIHIDRO-1H-INDOL-5-IL]-1,3-TIAZOLIDINA-2,4-DIONA, A SU PROCEDIMIENTO DE PREPARACIÓN ASÍ COMO A LAS FORMULACIONES FARMACÉUTICAS QUE LA CONTIENEN.
GT201600004A 2013-07-12 2016-01-11 Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen GT201600004A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1356870A FR3008411B1 (fr) 2013-07-12 2013-07-12 Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent

Publications (1)

Publication Number Publication Date
GT201600004A true GT201600004A (es) 2018-09-28

Family

ID=50424327

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600004A GT201600004A (es) 2013-07-12 2016-01-11 Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen

Country Status (47)

Country Link
US (2) US9925195B2 (es)
EP (1) EP3019497B1 (es)
JP (1) JP6532459B2 (es)
KR (2) KR20180028554A (es)
CN (1) CN105377843B (es)
AP (1) AP2016008976A0 (es)
AR (1) AR096882A1 (es)
AU (1) AU2014289059B2 (es)
CA (1) CA2916380C (es)
CL (1) CL2016000013A1 (es)
CR (1) CR20160012A (es)
CU (1) CU20160005A7 (es)
CY (1) CY1119259T1 (es)
DK (1) DK3019497T3 (es)
DO (1) DOP2016000005A (es)
EA (1) EA031526B1 (es)
ES (1) ES2632570T3 (es)
FR (1) FR3008411B1 (es)
GE (1) GEP201706712B (es)
GT (1) GT201600004A (es)
HK (1) HK1222172A1 (es)
HR (1) HRP20171060T1 (es)
HU (1) HUE032568T2 (es)
IL (1) IL243526B (es)
JO (1) JO3292B1 (es)
LT (1) LT3019497T (es)
MA (1) MA38759B1 (es)
MD (1) MD4507C1 (es)
ME (1) ME02735B (es)
MX (1) MX360291B (es)
MY (1) MY183197A (es)
NI (1) NI201600009A (es)
NZ (1) NZ715841A (es)
PE (1) PE20160079A1 (es)
PH (1) PH12016500017B1 (es)
PL (1) PL3019497T3 (es)
PT (1) PT3019497T (es)
RS (1) RS55945B1 (es)
RU (1) RU2680826C9 (es)
SA (1) SA516370388B1 (es)
SG (1) SG11201510570YA (es)
SI (1) SI3019497T1 (es)
TN (1) TN2015000566A1 (es)
TW (2) TW201630906A (es)
UA (1) UA114041C2 (es)
UY (1) UY35629A (es)
WO (1) WO2015004395A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245270B2 (en) * 2013-07-12 2019-04-02 Les Laboratoires Servier Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369359T1 (de) * 2000-02-15 2007-08-15 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
AU2002226877B2 (en) * 2000-10-17 2006-01-12 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
HUP0500111A3 (en) * 2001-12-27 2009-10-28 Theravance Indolinone derivatives useful as protein kinase inhibitors
WO2005040116A2 (en) * 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
RU2429223C2 (ru) * 2005-12-05 2011-09-20 Ксенопорт, Инк. Мезилатное пролекарство леводопы, его композиции и применение
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
UY35629A (es) 2015-01-30
JP2016523953A (ja) 2016-08-12
ME02735B (me) 2017-10-20
FR3008411B1 (fr) 2015-07-03
RS55945B1 (sr) 2017-09-29
DOP2016000005A (es) 2016-12-15
HK1222172A1 (zh) 2017-06-23
CR20160012A (es) 2016-02-08
EA031526B1 (ru) 2019-01-31
PL3019497T3 (pl) 2017-09-29
RU2680826C2 (ru) 2019-02-28
CA2916380A1 (fr) 2015-01-15
GEP201706712B (en) 2017-07-25
ES2632570T3 (es) 2017-09-14
EP3019497A1 (fr) 2016-05-18
AU2014289059B2 (en) 2017-05-25
PH12016500017A1 (en) 2016-04-18
DK3019497T3 (en) 2017-08-07
RU2016104642A (ru) 2017-08-17
MD4507C1 (ro) 2018-03-31
HUE032568T2 (hu) 2017-09-28
MX2016000332A (es) 2016-05-09
US20160151378A1 (en) 2016-06-02
MD4507B1 (ro) 2017-08-31
AU2014289059A1 (en) 2016-02-04
CU20160005A7 (es) 2016-05-30
KR20180028554A (ko) 2018-03-16
MA38759A1 (fr) 2018-01-31
SG11201510570YA (en) 2016-01-28
EP3019497B1 (fr) 2017-04-12
RU2680826C9 (ru) 2019-03-01
IL243526A0 (en) 2016-02-29
MA38759B1 (fr) 2018-09-28
CN105377843A (zh) 2016-03-02
CN105377843B (zh) 2019-03-05
US9925195B2 (en) 2018-03-27
HK1222655A1 (zh) 2017-07-07
CY1119259T1 (el) 2018-02-14
FR3008411A1 (fr) 2015-01-16
PH12016500017B1 (en) 2019-06-26
KR20160030399A (ko) 2016-03-17
NZ715841A (en) 2019-04-26
JP6532459B2 (ja) 2019-06-19
AP2016008976A0 (en) 2016-01-31
AR096882A1 (es) 2016-02-03
MX360291B (es) 2018-10-29
PE20160079A1 (es) 2016-02-06
IL243526B (en) 2019-09-26
NI201600009A (es) 2016-02-11
JO3292B1 (ar) 2018-09-16
TW201630906A (zh) 2016-09-01
HRP20171060T1 (hr) 2017-10-06
EA201600101A1 (ru) 2016-06-30
PT3019497T (pt) 2017-05-15
TW201504236A (zh) 2015-02-01
TN2015000566A1 (fr) 2017-04-06
MY183197A (en) 2021-02-18
UA114041C2 (xx) 2017-04-10
SA516370388B1 (ar) 2017-12-14
LT3019497T (lt) 2017-05-25
CA2916380C (fr) 2017-11-21
TWI554510B (zh) 2016-10-21
SI3019497T1 (sl) 2017-07-31
WO2015004395A1 (fr) 2015-01-15
US20180207171A1 (en) 2018-07-26
MD20160003A2 (ro) 2016-06-30
CL2016000013A1 (es) 2016-08-12

Similar Documents

Publication Publication Date Title
BR112016016158A2 (pt) Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
UY34772A (es) ?una formulación de fármaco de liberación retardada?.
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
UY35661A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen
PT3049117T (pt) Libertação de medicamentos mediada por ultrassons
PL2872497T3 (pl) Pochodne chromanylowe do leczenia choroby mitochondrialnej
HRP20181607T1 (hr) Stabilne oralne otopine za kombinirane aktivne farmaceutske sastojke
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CL2016001313A1 (es) Formulaciones listas de fertilizante líquido de bifentrina.
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
EP2889016A4 (en) DENTAL SYRINGE
BR112014026557A2 (pt) fralda descartável.
UY34807A (es) Derivados monocíclicos de heteroarilcicloalquil- diamina
HUE050945T2 (hu) Gyógyszerforma hatóanyagok nyújtott felszabadítására
EP2968195A4 (en) PHARMACEUTICAL FORMULATION WITH GLYCOSAMINOGLYCAN
BR112013027222A2 (pt) composição de liberação prolongada que contém peptídeos como ingrediente ativo
GT201600004A (es) Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1h- pirrol-2-il]metilen}-2-oxo-2,3-dihidro-1h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su preparación, y las formulaciones farmacéuticas que la contienen
BR112013031547A2 (pt) sistema de implante dentário.
GT201500124A (es) Forma sòlida de un derivado de dihidro-pirido-oxazina
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
FR2989199B1 (fr) Adaptateur electriquement actif
PT2922571T (pt) Formulações farmacêuticas que compreendem metaloporfirinas que contêm carborano